Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.
复制标题
DOI：
10.1002/ijc.24010
复制
发表时间：
2009-02-01
影响因子：
6.4
通讯作者：
Snijders, Peter J. F.
中科院分区：
文献类型：
--
作者：
Meijer, Chris J. L. M.;Berkhof, Johannes;Castle, Philip E.;Hesselink, Albertus T.;Franco, Eduardo L.;Ronco, Guglielmo;Arbyn, Marc;Bosch, F. Xavier;Cuzick, Jack;Dillner, Joakim;Heideman, Danielle A. M.;Snijders, Peter J. F.
鉴于高危HPV感染与宫颈癌之间存在很强的病因学联系，高危HPV检测现在被认为是基于细胞学的宫颈癌筛查的替代方法。许多测试系统已经开发出来，可以在一次检测中检测广泛的hrHPV类型。然而，对于筛查目的来说，高风险HPV的检测本身并不是有用的，除非它能提供高级别宫颈上皮内瘤变（CIN 2/3）或癌症的信息。用于筛查的候选高危HPV检测应在检测高级别CIN和宫颈癌的临床敏感性和特异性之间达到最佳平衡，以尽量减少对无宫颈病变的高危HPV阳性妇女的冗余或过度随访程序。来自各种大型筛选研究的数据表明，通过杂交捕获2和GP5+/6+ - PCR检测高危HPV在CIN 2/3检测方面的结果明显优于细胞学。这些研究的数据可以通过制定检测性能和特征的标准来指导将高危HPV检测转化为临床实践。在这些数据的基础上，我们制定了高危HPV检测要求的指南，用于宫颈筛查和候选HPV检测的验证指南。©2008 Wiley‐Liss, Inc。
Given the strong etiologic link between high‐risk HPV infection and cervical cancer high‐risk HPV testing is now being considered as an alternative for cytology‐based cervical cancer screening. Many test systems have been developed that can detect the broad spectrum of hrHPV types in one assay. However, for screening purposes the detection of high‐risk HPV is not inherently useful unless it is informative for the presence of high‐grade cervical intraepithelial neoplasia (CIN 2/3) or cancer. Candidate high‐risk HPV tests to be used for screening should reach an optimal balance between clinical sensitivity and specificity for detection of high‐grade CIN and cervical cancer to minimize redundant or excessive follow‐up procedures for high‐risk HPV positive women without cervical lesions. Data from various large screening studies have shown that high‐risk HPV testing by hybrid capture 2 and GP5+/6+‐PCR yields considerably better results in the detection of CIN 2/3 than cytology. The data from these studies can be used to guide the translation of high‐risk HPV testing into clinical practice by setting standards of test performance and characteristics. On the basis of these data we have developed guidelines for high‐risk HPV test requirements for primary cervical screening and validation guidelines for candidate HPV assays. © 2008 Wiley‐Liss, Inc.
登录
查看更多内容
影响因子：
168.9
作者：
Bulkmans, N. W. J.;Berkhof, J.;Meijer, C. J. L. M.
通讯作者：
Meijer, C. J. L. M.
影响因子：
9.4
作者：
Hesselink, A. T.;Bulkmans, N. W. J.;Snijders, P. J. F.
通讯作者：
Snijders, P. J. F.
影响因子：
51.1
作者：
Cogliano, V;Baan, R;El Ghissassi, F
通讯作者：
El Ghissassi, F
影响因子：
168.9
作者：
Cuzick, J;Szarewski, A;Sasieni, P
通讯作者：
Sasieni, P
影响因子：
6.4
作者：
Muñoz, N;Bosch, FX;Meijer, CJLM
通讯作者：
Meijer, CJLM